Integra LifeSciences Holdings (IART)

Receivables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	1,596,615	1,533,335	1,521,985	1,473,066	1,486,381	1,488,778	1,493,656	1,509,844	1,505,291	1,519,581	1,519,648	1,510,233	1,535,982	1,529,270	1,504,267	1,371,086	1,317,264	1,323,744	1,339,441	1,466,719
Receivables	US$ in thousands	272,370	248,298	271,155	241,092	259,327	256,270	258,663	253,995	263,465	248,268	237,361	234,010	231,831	222,232	229,823	223,542	225,532	218,184	179,143	245,546
Receivables turnover		5.86	6.18	5.61	6.11	5.73	5.81	5.77	5.94	5.71	6.12	6.40	6.45	6.63	6.88	6.55	6.13	5.84	6.07	7.48	5.97

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $1,596,615K ÷ $272,370K
= 5.86

The receivables turnover ratio for Integra LifeSciences Holdings fluctuated over the period analyzed. The ratio ranged from 5.61 to 7.48 during the period from March 31, 2020, to December 31, 2024. A higher receivables turnover ratio indicates that the company is collecting outstanding receivables more efficiently.

The analysis shows that there was an overall improvement in receivables turnover from mid-2020 to mid-2021, with a peak of 7.48 on June 30, 2020. However, the ratio started to decline gradually from mid-2021 onwards, reaching a low of 5.61 on June 30, 2024. This indicates a potential slowdown in the collection of receivables during that period.

Although there were fluctuations in the receivables turnover ratio, the general trend was relatively stable over the period, hovering around an average ratio of approximately 6. This stability suggests that Integra LifeSciences Holdings maintained a consistent level of efficiency in collecting receivables during the period under review.

Overall, the analysis of the receivables turnover ratio indicates how well Integra LifeSciences Holdings is managing its accounts receivable and collecting outstanding payments from customers.